SPTBN2 and cancer: Using the Genomics of Drug Sensitivity in Cancer dataset, an investigation of a possible correlation between SPTBN2 levels and drug sensitivity suggested that Vorinostat (a HDAC inhibitor) inversely correlates with SPTBN2 expression (Supplemental Fig. 3a).